Document is current
Any future updates will be listed below
-
Authors
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
Bando, Hiroko
Yamanaka, Takashi
Kadoya, Takayuki
Takahashi, Masato
Nagai, Shigenori E.
Ohtani, Shoichiro
Aruga, Tomoyuki
Suzuki, Eiji
Kikawa, Yuichiro
Yasojima, Hiroyuki
Kasai, Hiroi
Ishiguro, Hiroshi
Kawabata, Hidetaka
Morita, Satoshi
Haga, Hironori
Kataoka, Tatsuki R.
Uozumi, Ryuji
Ohno, Shinji
Toi, Masakazu
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000023162 at UMIN JapanDocuments that mention this clinical trial
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
https://doi.org/10.1007/s10549-021-06184-w
-
Funding
Funding for this research was provided by:
Japan Breast Cancer Research Group
Eisai Co., Ltd
- License Information
-
More Information
Article History
Received: 25 December 2020
Accepted: 5 March 2021
First Online: 25 March 2021
Declarations
:
: Dr. Masuda: remuneration and research funding to institution from AstraZeneca, Chugai, Eli Lilly, and Pfizer; remuneration from Eisai and Takeda; research funding to institution from Daiichi Sankyo, Kyowa Kirin, MSD, Nippon Kayaku and Novartis. Dr. Bando: remuneration from AstraZeneca, Chugai, Eisai, Kyowa Kirin, Nippon Kayaku, Novartis, Pfizer, and Taiho. Dr. Yamanaka: remuneration from Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa Kirin, Novartis, and Pfizer. Dr. Kadoya: none. Dr. Takahashi: remuneration from AstraZeneca, Eisai, Eli Lilly, and Pfizer. Dr. Nagai: remuneration from Chugai, Eisai, Eli Lilly, Novartis, Pfizer, and Taiho. Dr. Ohtani: remuneration from AstraZeneca, Chugai, Eisai, Eli Lilly, and Pfizer. Dr. Aruga: remuneration from Eisai, Eisai, and Pfizer. Dr. Suzuki: none. Dr. Kikawa: remuneration from Chugai, Eisai, Eli Lilly, Novartis, Pfizer, and Taiho. Dr. Yasojima: none. Dr. Kasai: funding from Eisai during the conduct of the study; remuneration from Chugai. Dr. Ishiguro: none. Dr. Kawabata: funding from Chugai, Daiichi Sankyo, MSD, and Novartis during the conduct of the study. Dr. Morita: remuneration from AstraZeneca, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, MSD, Pfizer, and Taiho. Dr. Haga: none. Dr. Kataoka: none. Dr. Uozumi: consultant/advisory role at CAC Croit, Eisai, and Sawai. Dr. Ohno: funding from Eisai and Taiho; remuneration from AstraZeneca, Chugai, Eisai, Eli Lilly, and Pfizer. Dr. Toi: remuneration and funding from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Kyowa Kirin, Nippon Kayaku, Pfizer, Shimadzu, Taiho, Takeda, and Yakult; remuneration from Eli Lilly, Exact Sciences, Konica Minolta, MSD, and Novartis; funding from AFI technology, GL Sciences, JBCRG Association, Luxonus, and Shionogi; consultant/advisory role for Athenex Oncology, Bertis, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Kansai Medical Net, Kyowa Kirin, Luxonus, and Terumo.
: The study complied with the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan. The study protocol was reviewed and approved by the institutional review board of each participating institution. All patients provided written informed consent at primary registration. Some of the study results were presented as a Mini Oral session at the ESMO Virtual Congress 2020.
